United States Últimas notícias

Anna Edwards, Guy Johnson, and Paul Dobson break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."

Brent crude rose $2.82, or 2.59%, to $111.64 per barrel Thursday as attacks in Saudi Arabia raised supply concerns.

Barclays (NYSE:BCS) reported third-quarter 2026 pre-tax profit of £2.3 billion, up 12%, while total group income increased 3% to £7.4 billion.

Cognizant (NASDAQ:CTSH) agreed to acquire Australia-based DyFlex Solutions, an SAP services provider employing more than 300 people across its operations.

Supernus (NASDAQ:SUPN) announced FDA recognition of seven years of orphan-drug exclusivity for ONAPGO, its treatment for motor fluctuations in advanced Parkinson's disease.

In a milestone for the UAE's domestic space industry, Altair-1, the first commercial satellite built in the country, was successfully launched in October 2026. Ahmad Belhoul Al Falasi, Chairman of the UAE Space Agency spoke to Bloomberg's Abeer Abu Omar on Horizons Middle East & Africa about the UAE's space ambitions.

Mid Penn Bancorp (NASDAQ:MPB) reported third-quarter 2026 net income available to common shareholders of $21.6 million, up 18.2% year over year.

Pharming Group (NASDAQ:PHAR) expects third-quarter 2026 revenue of approximately US$117.6 million, up 21% year over year, according to preliminary unaudited results.

argenx (NASDAQ:ARGX) reported third-quarter 2026 global product net sales of $1.7 billion, up 54%, supported by continued VYVGART sales growth.

The US State Department ordered the departure of non-emergency personnel and their families from Saudi Arabia amid escalating Houthi attacks on the kingdom. The latest strikes killed three people in two attacks on an Aramco oil field and an airport in Saudi Arabia's Eastern Province. Hasan Alhasan, Senior Fellow for Middle East Policy at the International Institute for Strategic Studies spoke to Bloomberg's Abeer Abu Omar on Horizons Middle East & Africa.

Nokia (NYSE:NOK) reported third-quarter 2026 net sales of €5.154 billion, up 10%, while reported operating profit declined 22% to €196 million.

Oculis (NASDAQ:OCS) reported new Phase 2 ACUITY findings showing reduced nerve injury biomarker increases with Privosegtor versus placebo at Day 5.